title: Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.
abstract: Despite advances in molecular characterization and lung cancer treatment in recent years, treatment options for patients diagnosed with squamous cell carcinoma of the lung (SCC) remain limited as actionable mutations are rarely detected in this subtype. This article reviews potential molecular targets and associated novel agents for the treatment of advanced SCC in the era of personalized medicine. Elements of various pathways includingepidermal growth factor receptor, PI3KCA, fibroblast growth factor receptor, retinoblastoma, cyclin-dependent kinases, discoidin domain receptor tyrosine kinase 2, andmesenchymal-to-epithelial transitionmay play pivotal roles in the development of SCC and are under investigation for drug development.
authors.affiliation: Division of Medical Oncology, Princess Margaret Cancer Centre , Toronto, ON , Canada.
authors.forename: Sara Victoria
authors.initials: SV
authors.lastname: Soldera
authors.affiliation: Division of Medical Oncology, Princess Margaret Cancer Centre , Toronto, ON , Canada.
authors.forename: Natasha B
authors.initials: NB
authors.lastname: Leighl
keywords: lung cancer; molecular sequence data; personalized medicine; squamous cell carcinoma; targeted therapy